Related Experiment Video
Updated: May 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes
Debra A Schaumberg1, Robert J Glynn, Alicia J Jenkins
1Division of Preventive Medicine, Brigham and Womens Hospital, Boston, Mass, USA. dschaumberg@rics.bwh.harvard.edu
Circulation
|May 4, 2005
Summary
Intensive therapy for type 1 diabetes affects inflammation markers differently. While it reduces some markers, it increases others, particularly high-sensitivity C-reactive protein (hsCRP) in those gaining weight, influencing atherosclerosis risk.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Immunology
Background:
- Type 1 diabetes mellitus (T1DM) increases cardiovascular disease (CVD) risk beyond conventional factors.
- Intensive diabetes therapy can lead to weight gain, potentially impacting CVD risk.
- Inflammation markers are linked to CVD risk and were investigated in relation to T1DM treatment.
Purpose of the Study:
- To examine the effect of intensive diabetes therapy on inflammation markers in T1DM patients.
- To assess how changes in inflammation markers relate to CVD risk factors.
- To understand the complex interplay between T1DM treatment, weight gain, and inflammation.
Main Methods:
- Analysis of serum samples from 385 participants in the Diabetes Control and Complications Trial (DCCT).
- Measurement of inflammatory biomarkers: hsCRP, sICAM-1, sVCAM-1, and sTNF-R1 at baseline and 3-year follow-up.
- Comparison of intensive versus conventional diabetes treatment groups, with adjustments for confounding factors.
Main Results:
- Intensive therapy significantly decreased sICAM-1 and increased sTNF-R1 levels.
- hsCRP levels increased in both groups, but significantly more in intensive therapy patients who gained substantial weight.
- sVCAM-1 levels decreased with intensive therapy, while sICAM-1 decreased significantly after adjustment.
Conclusions:
- Intensive therapy in T1DM has complex effects on inflammation, reducing sICAM-1 but increasing sTNF-R1 and hsCRP (in weight-gaining patients).
- The degree of weight gain during intensive therapy may influence atherosclerosis risk via hsCRP levels.
- These findings highlight the need to consider weight management alongside intensive therapy to mitigate CVD risk in T1DM.
More Related Videos
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
01:22Diabetes Mellitus: Type 2 and Gestational
5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Type I Diabetes II: Pathophysiology
121
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
121
01:19Type I Diabetes III: Clinical Manifestations
31
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
31
01:24Type II Diabetes II: Pathophysiology
36
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
36